MA46731A - Anticorps anti-tmprss2 et fragments de liaison à l'antigène - Google Patents

Anticorps anti-tmprss2 et fragments de liaison à l'antigène

Info

Publication number
MA46731A
MA46731A MA046731A MA46731A MA46731A MA 46731 A MA46731 A MA 46731A MA 046731 A MA046731 A MA 046731A MA 46731 A MA46731 A MA 46731A MA 46731 A MA46731 A MA 46731A
Authority
MA
Morocco
Prior art keywords
antigen binding
binding fragments
tmprss2 antibodies
tmprss2
antibodies
Prior art date
Application number
MA046731A
Other languages
English (en)
Other versions
MA46731B1 (fr
Inventor
Lisa Purcell
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA46731A publication Critical patent/MA46731A/fr
Publication of MA46731B1 publication Critical patent/MA46731B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention comprend un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement à tmprss2 et des procédés d'utilisation de tels anticorps et fragments pour traiter ou prévenir des infections virales (par exemple, des infections par le virus de la grippe).
MA46731A 2018-01-26 2019-01-24 Anticorps anti-tmprss2 et fragments de liaison à l'antigène MA46731B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622292P 2018-01-26 2018-01-26
PCT/US2019/014978 WO2019147831A1 (fr) 2018-01-26 2019-01-24 Anticorps anti-tmprss2 et fragments de liaison à l'antigène

Publications (2)

Publication Number Publication Date
MA46731A true MA46731A (fr) 2020-04-22
MA46731B1 MA46731B1 (fr) 2021-06-30

Family

ID=66102175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46731A MA46731B1 (fr) 2018-01-26 2019-01-24 Anticorps anti-tmprss2 et fragments de liaison à l'antigène

Country Status (26)

Country Link
US (3) US10941213B2 (fr)
EP (1) EP3638698B1 (fr)
JP (2) JP7834965B2 (fr)
KR (2) KR102911478B1 (fr)
CN (2) CN111936517B (fr)
AU (2) AU2019211406C1 (fr)
BR (1) BR112020015112A2 (fr)
CA (1) CA3089377A1 (fr)
CY (1) CY1124182T1 (fr)
DK (1) DK3638698T3 (fr)
ES (1) ES2864529T3 (fr)
HR (1) HRP20210876T1 (fr)
HU (1) HUE054403T2 (fr)
IL (2) IL276164B2 (fr)
LT (1) LT3638698T (fr)
MA (1) MA46731B1 (fr)
MD (1) MD3638698T2 (fr)
MX (2) MX2020007888A (fr)
PL (1) PL3638698T3 (fr)
PT (1) PT3638698T (fr)
RS (1) RS61825B1 (fr)
SG (1) SG11202006898TA (fr)
SI (1) SI3638698T1 (fr)
SM (1) SMT202100307T1 (fr)
WO (1) WO2019147831A1 (fr)
ZA (1) ZA202004494B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
BR112020015112A2 (pt) 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos
EP4034564A4 (fr) 2019-09-23 2023-12-13 Twist Bioscience Corporation Bibliothèques d'acides nucléiques variants pour des anticorps à domaine unique
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
BR112022014278A2 (pt) 2020-01-24 2022-09-20 Regeneron Pharma Conjugados de composto proteico-antiviral
EP4103619A1 (fr) * 2020-02-10 2022-12-21 Regeneron Pharmaceuticals, Inc. Anticorps anti-tmprss2 et fragments de liaison à l'antigène
WO2021190980A1 (fr) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimères pour l'évolution d'une souche virale
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
KR20230002612A (ko) * 2020-04-13 2023-01-05 매든 어드바이저스 엘엘씨 Ace2-표적화 조성물 및 covid-19의 치료 방법
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
US20230149536A1 (en) 2020-04-17 2023-05-18 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
AU2021282179A1 (en) 2020-05-26 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
MX2022014852A (es) 2020-06-03 2023-02-01 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
US12097212B2 (en) * 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
WO2021255217A1 (fr) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxine et conjugués d'amatoxine destinés à être utilisés dans l'inhibition de la réplication de virus à arn
CN111986818A (zh) * 2020-08-21 2020-11-24 南通大学 一种基于tmprss2的新冠covid-19治疗药物筛选系统
IL300917A (en) 2020-09-04 2023-04-01 Univ Rutgers Sars-cov-2 vaccines and antibodies
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
WO2022115503A1 (fr) 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Traitement et prévention d'une infection à coronavirus
CN112538494A (zh) * 2020-12-08 2021-03-23 武汉华美生物工程有限公司 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法
WO2022133182A1 (fr) * 2020-12-18 2022-06-23 Chan Zuckerberg Biohub, Inc. Procédé de traitement d'une infection au coronavirus
WO2022184659A1 (fr) 2021-03-01 2022-09-09 Quadrucept Bio Limited Domaines d'anticorps et multimères
WO2022187626A1 (fr) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anticorps de glycoprotéine anti-sars-cov-2 à variante spike et fragments de liaison à l'antigène
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
EP4370210A1 (fr) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-glycoprotéine de spicule du sars-cov-2 et fragments de liaison à l'antigène
US20250277059A1 (en) * 2022-04-12 2025-09-04 Riken Antibody used to treat coronavirus infection
WO2023220712A1 (fr) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Protéases hôtes essentielles pour la propagation de parainfluenza dans le poumon humain : cibles potentielles pour interventions antivirales
CN116003611B (zh) * 2022-08-17 2024-02-27 中南大学湘雅医院 抗tmprss2抗体及其用途
WO2024252183A1 (fr) * 2023-06-08 2024-12-12 Institut Pasteur Anticorps à domaine unique dirigés contre la transmembrane-sérine protéase 2 humaine (tmprss2)
WO2025072792A1 (fr) * 2023-09-28 2025-04-03 The Regents Of The University Of California Procédés d'identification et de traitement de maladies caractérisées par une expression spécifique d'allèle

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
ATE429643T1 (de) 2000-07-12 2009-05-15 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2008127347A1 (fr) 2006-07-21 2008-10-23 Diadexus, Inc. Compositions d'anticorps anti-pro 115 et procédés d'utilisation
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AU2013215254B2 (en) * 2012-01-31 2017-08-31 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
BR112014025339A8 (pt) * 2012-04-16 2018-01-16 Regeneron Pharma método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
EP3895529B1 (fr) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rongeurs ayant un gène tmprss humanisé
JP2020514396A (ja) * 2017-03-22 2020-05-21 ザ チルドレンズ メディカル センター コーポレーション Ｌｒｐ１結合剤およびその使用
BR112020015112A2 (pt) 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos

Also Published As

Publication number Publication date
US20190300625A1 (en) 2019-10-03
MD3638698T2 (ro) 2021-07-31
EP3638698B1 (fr) 2021-03-03
IL312961A (en) 2024-07-01
CY1124182T1 (el) 2022-05-27
KR20250133488A (ko) 2025-09-05
MA46731B1 (fr) 2021-06-30
JP7834965B2 (ja) 2026-03-25
LT3638698T (lt) 2021-04-12
MX2020007888A (es) 2020-09-07
IL276164B2 (en) 2024-11-01
SG11202006898TA (en) 2020-08-28
IL276164B1 (en) 2024-07-01
IL276164A (en) 2020-09-30
HUE054403T2 (hu) 2021-09-28
PT3638698T (pt) 2021-04-06
CN120290578A (zh) 2025-07-11
JP2024009962A (ja) 2024-01-23
KR102911478B1 (ko) 2026-01-14
HRP20210876T1 (hr) 2021-07-09
SMT202100307T1 (it) 2021-07-12
KR20200115576A (ko) 2020-10-07
US12065506B2 (en) 2024-08-20
AU2019211406C1 (en) 2025-07-17
SI3638698T1 (sl) 2021-07-30
RS61825B1 (sr) 2021-06-30
AU2025204183A1 (en) 2025-06-26
BR112020015112A2 (pt) 2021-04-06
ZA202004494B (en) 2022-05-25
AU2025204183A9 (en) 2026-03-19
US10941213B2 (en) 2021-03-09
US20210230303A1 (en) 2021-07-29
US20230265216A1 (en) 2023-08-24
DK3638698T3 (da) 2021-04-26
US20220081489A9 (en) 2022-03-17
PL3638698T3 (pl) 2021-09-06
AU2019211406B2 (en) 2025-03-06
WO2019147831A1 (fr) 2019-08-01
CA3089377A1 (fr) 2019-08-01
AU2019211406A1 (en) 2020-08-13
CN111936517A (zh) 2020-11-13
MX2024006462A (es) 2024-06-11
CN111936517B (zh) 2025-04-18
ES2864529T3 (es) 2021-10-14
JP2021511058A (ja) 2021-05-06
US11603413B2 (en) 2023-03-14
EP3638698A1 (fr) 2020-04-22

Similar Documents

Publication Publication Date Title
MA46731B1 (fr) Anticorps anti-tmprss2 et fragments de liaison à l'antigène
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
CR20200579A (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
NZ743713A (en) Human immunodeficiency virus neutralizing antibodies
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
DE602006013029D1 (de) Anti-egfr-antikörper
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
MA40474A (fr) Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l'antigène, composition médicinale et son utilisation
CR20220660A (es) Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
BR112024000744A2 (pt) Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
CN115666649A (zh) 一种新型冠状病毒抗体的药物组合物及其用途
CA3179819A1 (fr) Anticorps anti-glycoproteine spike du sars-cov 2 et leurs fragments de liaison a l'antigene
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
WO2022011110A3 (fr) Compositions et méthodes de diagnostic et de traitement de l'infection par le virus sars-cov-2
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
WO2020191181A9 (fr) Anticorps monoclonaux pour la prévention et le traitement d'infections virales de l'herpès simplex
WO2023129870A3 (fr) Anticorps reconnaissant spécifiquement c5ar1 et utilisations associées
WO2020053742A3 (fr) Anticorps peptidiques anti-hla-vhb
WO2023019174A3 (fr) Anticorps contre le sars-cov-2